http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115240874-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc50c42c1b09208fa3ad58b6cff2426b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C10-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16C10-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H70-40 |
| filingDate | 2022-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1c2f77f374c28bb59b08a9f48635b49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c68334e5ebe4e94645e4318f6889db9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b3b7aa5d65e17ca8bebf1e76fee3970 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7607c3f5bd254a0ff9d5e00cb8b98b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fd1f36d6b59ebdb9df2f31d50e6c017 |
| publicationDate | 2022-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-115240874-A |
| titleOfInvention | Method for constructing population pharmacokinetic model of glucokinase activator and its application |
| abstract | The invention provides a method for constructing a population pharmacokinetic model of a glucokinase activator and an application thereof, belonging to the field of drug analysis. The present invention quantitatively explores the PB-201-treated type 2 diabetes mellitus (T2DM) in vivo by analyzing the relationship between the pharmacokinetics and pharmacodynamics (dynamic blood glucose) of Phase I clinical studies in China by using the population method. The influence of intraday fluctuation rhythm of ambulatory blood glucose, meal and administration time on blood glucose fluctuation, and further used ambulatory blood glucose as a pharmacodynamic index to construct a population pharmacokinetic model of glucokinase activator, which is useful for the individualization of PB‑201 The design of the dosing regimen has important clinical implications. At the same time, the present application also provides a new idea for the construction of a population pharmacokinetic model. |
| priorityDate | 2022-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 167.